{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:05:25Z","timestamp":1792609525285,"version":"4.5.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0395_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a highly accurate blood-based biomarker of Alzheimer\u2019s disease (AD) pathology. As disease-modifying anti-amyloid therapies enter clinical practice, scalable biomarkers with robust and clinically interpretable decision thresholds are required. However, evidence on inter-platform comparability and threshold transferability across automated assays remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0395_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a head-to-head comparison of two automated platforms\u00a0\u2013\u00a0Lumipulse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      G600II and Cobas\n                      <jats:sup>\u00ae<\/jats:sup>\n                      e801\u00a0\u2013\u00a0for plasma p-tau217 measurement in 157 consecutive patients undergoing lumbar puncture. Amyloid status was defined by the CSF A\u03b242\/A\u03b240 ratio. Agreement was assessed using intraclass correlation coefficients and Bland\u2013Altman analysis. Diagnostic performance was evaluated using receiver operating characteristic curves. Optimal thresholds were derived using the Youden index. Predefined rule-out (\u226595\u202f% sensitivity) and rule-in (\u226595\u202f% specificity) thresholds were explored, alongside alternative\u00a0\u226590\u202f% thresholds.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0395_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Agreement between platforms was excellent (Spearman \u03c1=0.922; ICC(3,1)=0.922), although Bland\u2013Altman analysis revealed a small systematic difference in absolute concentrations. Both assays showed comparable diagnostic accuracy for amyloid positivity (AUC=0.923 for both platforms; DeLong p&gt;0.99), but required platform-specific thresholds. Rule-out and rule-in thresholds achieved\u00a0\u226595\u202f% sensitivity and specificity, with strong likelihood ratios and excellent categorical agreement (weighted \u03ba=0.870). Approximately 30\u202f% of individuals were classified in the grey zone. Using\u00a0\u226590\u202f% thresholds reduced the grey zone to 9\u201313\u202f% while maintaining excellent agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0395_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma p-tau217 demonstrates high analytical concordance and comparable diagnostic performance across automated platforms despite systematic concentration differences. Platform-specific dual-threshold strategies may support structured and clinically interpretable implementation, pending prospective multicenter validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0395","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:11:26Z","timestamp":1778008286000},"page":"1974-1985","source":"Crossref","is-referenced-by-count":2,"title":["Analytical agreement and platform-specific decision thresholds for plasma p-tau217 measured on Lumipulse G600II and Cobas e801 in a paired CSF\u2013plasma cohort"],"prefix":"10.1515","volume":"64","author":[{"given":"Mar\u00eda","family":"Mart\u00ednez-Bujidos","sequence":"first","affiliation":[{"name":"Laboratory Medicine Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Neurology Commission , SEMEDLAB (Spanish Society of Medical Laboratory) , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Department of Neurology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Arnau","family":"Pulido-Gracia","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Vilas","sequence":"additional","affiliation":[{"name":"Department of Neurology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Neurology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Ispierto","sequence":"additional","affiliation":[{"name":"Department of Neurology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Morales-Indiano","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Pastor","sequence":"additional","affiliation":[{"name":"Department of Neurology , Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Department of Neuroscience , Health Sciences Research Institute Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026091512595704342_j_cclm-2026-0395_ref_001","doi-asserted-by":"crossref","unstructured":"Dobson, R, Patterson, K, Malik, R, Mandal, U, Asif, H, Humphreys, R, et al.. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease. J\u00a0Neurol Neurosurg Psychiatry 2024;95:796\u2013803. https:\/\/doi.org\/10.1136\/jnnp-2024-333468.","DOI":"10.1136\/jnnp-2024-333468"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_002","doi-asserted-by":"crossref","unstructured":"Daly, T, Kepp, KP, Imbimbo, BP. Are lecanemab and donanemab disease-modifying therapies? Alzheimer\u2019s Dement 2024;20:6659\u201361. https:\/\/doi.org\/10.1002\/alz.14114.","DOI":"10.1002\/alz.14114"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_003","doi-asserted-by":"crossref","unstructured":"Villain, N, Planche, V, Lilamand, M, Cordonnier, C, Soto-Martin, M, Mollion, H, et al.. Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French Federation of memory clinics. J\u00a0Prev Alzheimers Dis 2025;12:100094. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094.","DOI":"10.1016\/j.tjpad.2025.100094"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_004","doi-asserted-by":"crossref","unstructured":"Jack, CRJ, Andrews, JS, Beach, TG, Buracchio, T, Dunn, B, Graf, A, et al.. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimer\u2019s Dement 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","DOI":"10.1002\/alz.13859"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_005","doi-asserted-by":"crossref","unstructured":"Hansson, O, Zetterberg, H, Buchhave, P, Londos, E, Blennow, K, Minthon, L. Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228\u201334. https:\/\/doi.org\/10.1016\/s1474-4422(06)70355-6.","DOI":"10.1016\/S1474-4422(06)70355-6"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_006","doi-asserted-by":"crossref","unstructured":"Blennow, K, Zetterberg, H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J\u00a0Intern Med 2018;284:643\u201363. https:\/\/doi.org\/10.1111\/joim.12816.","DOI":"10.1111\/joim.12816"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_007","doi-asserted-by":"crossref","unstructured":"Molinuevo, JL, Ayton, S, Batrla, R, Bednar, MM, Bittner, T, Cummings, J, et al.. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol 2018;136:821\u201353. https:\/\/doi.org\/10.1007\/s00401-018-1932-x.","DOI":"10.1007\/s00401-018-1932-x"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_008","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Janelidze, S, Quiroz, YT, Zetterberg, H, Lopera, F, Stomrud, E, et al.. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs. other neurodegenerative disorders. JAMA 2020;324:772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","DOI":"10.1001\/jama.2020.12134"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_009","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez-Calvet, M, Abdelnour, C, Alcolea, D, Mendi\u00f3roz-Iriarte, M, Balasa, M, Morenas-Rodr\u00edguez, E, et al.. Biomarcadores en sangre para la enfermedad de Alzheimer: posicionamiento y recomendaciones de uso del Grupo de Estudio de Conducta y Demencias de la Sociedad Espa\u00f1ola de Neurolog\u00eda. Neurologia 2025;40:700\u2013712. https:\/\/doi.org\/10.1016\/j.nrl.2024.08.002.","DOI":"10.1016\/j.nrl.2024.08.002"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_010","doi-asserted-by":"crossref","unstructured":"Hansson, O, Edelmayer, RM, Boxer, AL, Carrillo, MC, Mielke, MM, Rabinovici, GD, et al.. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement 2022;18:2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","DOI":"10.1002\/alz.12756"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_011","doi-asserted-by":"crossref","unstructured":"Zetterberg, H, Bendlin, BB. Biomarkers for Alzheimer\u2019s disease: preparing for a new era of disease-modifying therapies. Mol Psychiatr 2021;26:296\u2013308. https:\/\/doi.org\/10.1038\/s41380-020-0721-9.","DOI":"10.1038\/s41380-020-0721-9"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_012","unstructured":"Janelidze, S, Stomrud, E, Palmqvist, S, Smith, R, Beach, TG, Serrano, GE, et al.. Plasma p-tau217 in Alzheimer\u2019s disease: relationship to amyloid and tau pathology. Nat Med 2020;26:387\u201397."},{"key":"2026091512595704342_j_cclm-2026-0395_ref_013","doi-asserted-by":"crossref","unstructured":"Thijssen, EH, La Joie, R, Wolf, A, Strom, A, Wang, P, Iaccarino, L, et al.. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 2020;26:387\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2.","DOI":"10.1038\/s41591-020-0762-2"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_014","doi-asserted-by":"crossref","unstructured":"Schindler, SE, Petersen, KK, Saef, B, Tosun, D, Shaw, LM, Zetterberg, H, et al.. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimer\u2019s Dement 2024;20:8074\u201396. https:\/\/doi.org\/10.1002\/alz.14315.","DOI":"10.1002\/alz.14315"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_015","doi-asserted-by":"crossref","unstructured":"Ashton, NJ, Pascoal, TA, Karikari, TK, Benedet, AL, Lantero-Rodriguez, J, Brinkmalm, G, et al.. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 2021;141:709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","DOI":"10.1007\/s00401-021-02275-6"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_016","doi-asserted-by":"crossref","unstructured":"Keshavan, A, Heslegrave, A, Zetterberg, H, Schott, JM. Blood biomarkers for Alzheimer\u2019s disease: much promise, cautious progress. Mol Diagn Ther 2017;21:13\u201322. https:\/\/doi.org\/10.1007\/s40291-016-0241-0.","DOI":"10.1007\/s40291-016-0241-0"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_017","doi-asserted-by":"crossref","unstructured":"O\u2019Bryant, SE, Mielke, MM, Rissman, RA, Lista, S, Vanderstichele, H, Zetterberg, H, et al.. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer\u2019s Dement 2017;13:45\u201358. https:\/\/doi.org\/10.1016\/j.jalz.2016.09.014.","DOI":"10.1016\/j.jalz.2016.09.014"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_018","doi-asserted-by":"crossref","unstructured":"Ashton, NJ, Keshavan, A, Brum, WS, Hye, A, Passmore, P, Seripa, D, et al.. The Alzheimer\u2019s association global biomarker standardization consortium (GBSC) plasma phospho-tau round robin study. Alzheimer\u2019s Dement 2025;21. https:\/\/doi.org\/10.1002\/alz.14508.","DOI":"10.1101\/2024.08.22.24312244"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_019","doi-asserted-by":"crossref","unstructured":"Warmenhoven, N, Salvad\u00f3, G, Janelidze, S, Mattsson-Carlgren, N, Bali, D, Ordu\u00f1a Dolado, A, et al.. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 2025;148:416\u201331. https:\/\/doi.org\/10.1093\/brain\/awae346.","DOI":"10.1093\/brain\/awae346"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_020","doi-asserted-by":"crossref","unstructured":"Ahn, J, Lee, EH, Yoo, H, Kim, SH, Jang, H, Kim, HJ, et al.. Tailoring thresholds for interpreting plasma p-tau217 levels. J\u00a0Neurol Neurosurg Psychiatry 2025;96:722\u20137. https:\/\/doi.org\/10.1136\/jnnp-2025-335830.","DOI":"10.1136\/jnnp-2025-335830"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_021","doi-asserted-by":"crossref","unstructured":"Therriault, J, Brum, WS, Trudel, L, Ashton, NJ, Benedet, AL, Karikari, TK, et al.. Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 2025;24:740\u201352. https:\/\/doi.org\/10.1016\/s1474-4422(25)00227-3.","DOI":"10.1016\/S1474-4422(25)00227-3"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_022","unstructured":"Hansson, O. Biomarkers for precision medicine in Alzheimer\u2019s disease. Nat Rev Neurol 2021;17:469\u201382."},{"key":"2026091512595704342_j_cclm-2026-0395_ref_023","doi-asserted-by":"crossref","unstructured":"Mielke, MM, Dage, JL, Frank, RD, Algeciras-Schimnich, A, Knopman, DS, Lowe, VJ, et al.. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 2022;28:1398\u2013405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2.","DOI":"10.1038\/s41591-022-01822-2"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_024","doi-asserted-by":"crossref","unstructured":"Schindler, SE, Bollinger, JG, Ovod, V, Mawuenyega, KG, Li, Y, Gordon, BA, et al.. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 2019:93\u2013e1659. https:\/\/doi.org\/10.1212\/wnl.0000000000008081.","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_025","doi-asserted-by":"crossref","unstructured":"Mansilla, A, Canyelles, M, Ferrer, R, Rotllan, N, Rivas-Urbina, A, Tondo, M, et al.. Effects of storage conditions on the stability of blood markers for the diagnosis of Alzheimer\u2019s disease. Clin Chem Lab Med 2023;61:1580\u20139. https:\/\/doi.org\/10.1515\/cclm-2023-0245.","DOI":"10.1515\/cclm-2023-0245"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_026","doi-asserted-by":"crossref","unstructured":"Alcolea, D, Clarim\u00f3n, J, Carmona-Iragui, M, Ill\u00e1n-Gala, I, Morenas-Rodr\u00edguez, E, Barroeta, I, et al.. The sant pau initiative on neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer\u2019s Dement 2019;5:597\u2013609. https:\/\/doi.org\/10.1016\/j.trci.2019.09.005.","DOI":"10.1016\/j.trci.2019.09.005"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_027","doi-asserted-by":"crossref","unstructured":"Janelidze, S, Teunissen, CE, Zetterberg, H, Allu\u00e9, JA, Sarasa, L, Eichenlaub, U, et al.. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol 2021;78:1375\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180.","DOI":"10.1001\/jamaneurol.2021.3180"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_028","doi-asserted-by":"crossref","unstructured":"Ashton, NJ, Brum, WS, Di Molfetta, G, Benedet, AL, Arslan, B, Jonaitis, E, et al.. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 2024;81:255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_029","doi-asserted-by":"crossref","unstructured":"Janelidze, S, Mattsson, N, Palmqvist, S, Smith, R, Beach, TG, Serrano, GE, et al.. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 2020;26:379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1.","DOI":"10.1038\/s41591-020-0755-1"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_030","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Tideman, P, Cullen, N, Zetterberg, H, Blennow, K, Dage, JL, et al.. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 2021;27:1034\u201342. https:\/\/doi.org\/10.1038\/s41591-021-01348-z.","DOI":"10.1038\/s41591-021-01348-z"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_031","doi-asserted-by":"crossref","unstructured":"Therriault, J, Benedet, AL, Pascoal, TA, Mathotaarachchi, S, Savard, M, Chamoun, M, et al.. APOE\u03b54 potentiates the relationship between amyloid-\u03b2 and tau pathologies. Mol Psychiatr 2021;26:5977\u201388. https:\/\/doi.org\/10.1038\/s41380-020-0688-6.","DOI":"10.1038\/s41380-020-0688-6"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_032","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren, N, Janelidze, S, Palmqvist, S, Cullen, N, Svenningsson, AL, Strandberg, O, et al.. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 2020;143:3234\u201341. https:\/\/doi.org\/10.1093\/brain\/awaa286.","DOI":"10.1093\/brain\/awaa286"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_033","doi-asserted-by":"crossref","unstructured":"Jack, CRJ, Bennett, DA, Blennow, K, Carrillo, MC, Dunn, B, Haeberlein, SB, et al.. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_034","doi-asserted-by":"crossref","unstructured":"Schindler, SE, Galasko, D, Pereira, AC, Rabinovici, GD, Salloway, S, Su\u00e1rez-Calvet, M, et al.. Acceptable performance of blood biomarker tests of amyloid pathology\u00a0\u2013\u00a0recommendations from the global CEO initiative on Alzheimer\u2019s disease. Nat Rev Neurol 2024;20:426\u201339. https:\/\/doi.org\/10.1038\/s41582-024-00977-5.","DOI":"10.1038\/s41582-024-00977-5"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_035","doi-asserted-by":"crossref","unstructured":"Arslan, B, Gobom, J, Andreasson, U, Montoliu-Gaya, L, Benedet, AL, Dittrich, A, et al.. Analytical and clinical validation of the Lumipulse G plasma p-tau217 assay for clinical implementation. Alzheimers Dement 2026;22:e71374. https:\/\/doi.org\/10.1002\/alz.71374.","DOI":"10.1002\/alz.71374"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_036","doi-asserted-by":"crossref","unstructured":"Brum, WS, Cullen, NC, Janelidze, S, Ashton, NJ, Zimmer, ER, Therriault, J, et al.. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 2023;3:1079\u201390. https:\/\/doi.org\/10.1038\/s43587-023-00471-5.","DOI":"10.1038\/s43587-023-00471-5"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_037","doi-asserted-by":"crossref","unstructured":"Ashton, NJ, Leuzy, A, Karikari, TK, Mattsson-Carlgren, N, Dodich, A, Boccardi, M, et al.. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imag 2021;48:2140\u201356. https:\/\/doi.org\/10.1007\/s00259-021-05253-y.","DOI":"10.1007\/s00259-021-05253-y"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_038","doi-asserted-by":"crossref","unstructured":"Arslan, B, Gobom, J, Andreasson, U, Gonzalez-Ortiz, F, Ashton, NJ, Zetterberg, H, et al.. Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization. Clin Chem Lab Med 2025;64:e70\u2013e74. https:\/\/doi.org\/10.1515\/cclm-2025-1192.","DOI":"10.1515\/cclm-2025-1192"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_039","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Warmenhoven, N, Anastasi, F, Pilotto, A, Janelidze, S, Tideman, P, et al.. Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med 2025;31:2036\u201343. https:\/\/doi.org\/10.1038\/s41591-025-03622-w.","DOI":"10.1038\/s41591-025-03622-w"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_040","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Stomrud, E, Cullen, N, Janelidze, S, Manuilova, E, Jethwa, A, et al.. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 2023;19:1204\u201315. https:\/\/doi.org\/10.1002\/alz.12751.","DOI":"10.1002\/alz.12751"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_041","doi-asserted-by":"crossref","unstructured":"Bornhorst, JA, Lundgreen, CS, Weigand, SD, Figdore, DJ, Wiste, H, Griswold, M, et al.. Quantitative assessment of the effect of chronic kidney disease on plasma p-tau217 concentrations. Neurology 2025;104. https:\/\/doi.org\/10.1212\/wnl.0000000000210287.","DOI":"10.1212\/WNL.0000000000210287"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_042","doi-asserted-by":"crossref","unstructured":"Janelidze, S, Barth\u00e9lemy, NR, He, Y, Bateman, RJ, Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol 2023;80:516\u201322. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","DOI":"10.1001\/jamaneurol.2023.0199"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_043","doi-asserted-by":"crossref","unstructured":"Yun, J, Lee, J, Shin, D, Kim, S, Jang, H, Kim, HJ, et al.. Plasma phosphorylated tau 217 cutoffs for amyloid pathology and kidney function, body mass index, and anemia. JAMA Neurol 2026;83:269\u2013279. https:\/\/doi.org\/10.1001\/jamaneurol.2025.5530.","DOI":"10.1001\/jamaneurol.2025.5530"},{"key":"2026091512595704342_j_cclm-2026-0395_ref_044","doi-asserted-by":"crossref","unstructured":"Palmqvist, S, Whitson, HE, Allen, LA, Suarez-Calvet, M, Galasko, D, Karikari, TK, et al.. Alzheimer\u2019s association clinical practice guideline\u00a0on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimer\u2019s Dement 2025;21. https:\/\/doi.org\/10.1002\/alz.70535.","DOI":"10.1002\/alz.70535"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0395\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:03:44Z","timestamp":1789477424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0395\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/cclm-2026-0395"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0395","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}